Effient Beats Plavix In A Cost Study, But Will The Results Pass Muster With Payers?
This article was originally published in The Pink Sheet Daily
Medco response: Study may not have shown a cost advantage for Effient if Plavix non-responders had been excluded.
You may also be interested in...
Medco is working to generate cost effectiveness data for Bristol-Myers Squibb's anti-clotting blockbuster Plavix in anticipation of the launch of clopidogrel generics in 2011
When Lilly's Effient (prasugrel) finally cleared FDA July 10, the first thing everyone noticed is the "black box" warning of a potential increased risk of bleeding associated with the antithrombotic drug
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.